Novo Nordisk A/S (NYSE:NVO) Stock Price Down 1.7% – Here’s Why

Novo Nordisk A/S (NYSE:NVO)’s stock price dropped 1.7% on Thursday . The company traded as low as $58.80 and last traded at $59.30. Approximately 15,753,189 shares were traded during trading, a decline of 31% from the average daily volume of 22,934,711 shares. The stock had previously closed at $60.33.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Very strong launch demand for Wegovy pill: IQVIA data show the pill tracked over 26,000 U.S. prescriptions in its second full week, signaling rapid uptake that supports revenue upside and market share gains in the obesity market. Novo’s Wegovy pill tracks over 26,000 prescriptions
• Positive Sentiment: Early sales momentum reinforced by reporting of ~18,000 U.S. prescriptions in week one and commentary that demand is “strong out of the gate,” which supports upside to near‑term sales and investor sentiment. Demand for Novo Nordisk’s Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?
• Neutral Sentiment: Analyst view is mixed — one upgrade highlights first‑mover advantage, strong cash and aggressive U.S. marketing but also flags high valuation and potential for near‑term profit‑taking, leading to a cautious “Hold” posture. Novo Nordisk: Momentum Meets Headwinds Before Earnings (Upgrade)
• Neutral Sentiment: Public profile of Novo’s weight‑loss boom is increasing (e.g., a new Danish theatre piece), which is PR‑positive but not directly material to near‑term financials. New play in Denmark charts Novo Nordisk’s weight loss boom
• Negative Sentiment: Leadership change in China: Senior VP and head of China Christine Zhou will step down at end‑of‑March — a potential disruption given China’s importance for growth and ongoing market expansion. Novo Nordisk’s China President Zhou to step down in March
• Negative Sentiment: Near‑term headwinds flagged: analysts warn of slowing Wegovy/Ozempic momentum, pricing pressure and stronger competition that could limit upside to sales growth and margins into the Q4 earnings release. Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

Wall Street Analyst Weigh In

Several research firms recently commented on NVO. Jefferies Financial Group started coverage on Novo Nordisk A/S in a report on Monday, October 27th. They issued an “underperform” rating for the company. Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Morgan Stanley reiterated an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $57.79.

Novo Nordisk A/S Price Performance

The firm has a market cap of $265.23 billion, a P/E ratio of 17.27 and a beta of 0.66. The stock’s 50-day simple moving average is $53.44 and its two-hundred day simple moving average is $54.50. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Large investors have recently added to or reduced their stakes in the stock. True Wealth Design LLC boosted its holdings in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the period. NewSquare Capital LLC raised its position in shares of Novo Nordisk A/S by 174.1% in the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after acquiring an additional 282 shares in the last quarter. Guerra Advisors Inc bought a new position in Novo Nordisk A/S in the third quarter worth about $25,000. Strengthening Families & Communities LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $30,000. Finally, Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S in the second quarter worth $37,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.